CSACI 71ST ANNUAL SCIENTIFIC MEETING RÉUNION...

CSACI 71ST ANNUAL SCIENTIFIC MEETING

71e RÉUNION ANNUELLE SCIENTIFIQUE DE LA SCAIC

September 28 to October 2, 2016 Du 28 septembre au 2 octobre 2016 Le Westin Montréal Montréal, Québec

Canadian Society of Allergy and Clinical Immunology La Société canadienne d’allergie et d’immunologie clinique

PROGRAM PROGRAMME

CANADIAN SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY

REGISTRATION DESK HOURS

FOYER (Outside of MONTRÉAL Ballroom)

Wednesday, September 28 15:00-18:00 Thursday, September 29 06:45-17:00 Friday, September 30 06:45-17:00 Saturday, October 1 06:45-16:00 Sunday, October 2 06:45-12:00

Plan to visit the Exhibit area

and meet the CSACI Sponsors

EXHIBIT DATES AND HOURS (recommended)

Friday, September 30 06:45-15:00 Saturday, October 1 06:45-14:00 Sunday, October 2 06:45-11:00

Have sponsor/exhibitor representatives

initial your “Passport” and enter to win a (1) $600 gift certificate from Apple!

MEETING LOCATION Le Westin Montréal

270 rue Saint Antoine Ouest, Montréal, QC H2Y 0A3


Welcome,

We are very proud to host our 71st meeting of the Canadian Society of Allergy and Clinical Immunology. This year brings together an outstanding faculty of Canadian and international speakers who will share their expertise and insights as they cover the wide spectrum of clinical and basic sciences. As the primary Canadian gathering for the allergy community, it will provide an excellent opportunity for specialists and researchers in the field of allergy, asthma, and clinical immunology as well as allied health professionals from Canada and around the world to meet and share their knowledge in an atmosphere conducive to medical, scientific and social interaction. Have a great meeting!

Dr. Sandy Kapur CSACI President

SAVE THE DATE 2017 CSACI ASM October 11-15, 2017 Allstream Center and Hotel X Toronto, ON


2016 ANNUAL SCIENTIFIC MEETING PLANNING COMMITTEE Dr. Sandy Kapur, CSACI President Dr. Paul Keith, 2016 Program Chair Dr. David Fischer, CSACI Vice-President, CPD Committee Dr. Harold Kim, CSACI Treasurer, CPD Committee Dr. Susan Waserman, CAAIF President, OSCE Chair, CPD Committee Dr. Zainab Abdurrahman, NREP Co-Chair Dr. Dean Befus, CSACI Board Dr Jean-Nicolas Boursiquot, 2016 Program Committee Dr. Edmond Chan, CSACI Board Dr Hugo Chapdelaine, 2016 Program Committee Dr. Lori Connors, CPD Committee Chair Dr. Anne Ellis, FIT Bowl Chair and Abstract Co-Chair Dr. David Fahmy, FIT Representative Ms. Linda Kirste, Allied Health Co-Chair Dr. Jason Lee, Asthma Section Chair Dr. Sean Mace, Rhinosinusitis Chair Dr. Doug Mack, Anaphylaxis Chair Dr. Bruce Mazer, 2016 Program Committee Dr. Christine McCusker, 2016 Program Committee Dr. Elaine Medoff, 2016 Program Committee Dr. Andy O’Keefe, NREP Co-Chair Dre Marie-Noel Primeau, 2016 Program Committee Ms. Jo-Anne St-Vincent, Allied Health Co-Chair Dr. Stuart Turvey, Immunology Chair Dr. Hari Vliagoftis, Abstract Co-Chair Ms. Louise Tremblay, Executive Director Ms. Alexi Campbell, Manager PROGRAM OBJECTIVES The CSACI Annual Scientific meeting’s main objectives are to provide current information about the diagnosis, treatment and management in allergy, asthma and immunology. This meeting is a setting for interdisciplinary exchange among professionals and provides an excellent opportunity for participants to interact with colleagues and experts in the field. By participating in this conference, attendees can expect to evaluate new trends, techniques, therapies and diagnostic procedures in allergy, asthma and immunology.

WHY YOU SHOULD ATTEND! As the premier meeting of the allergy, asthma and immunology community, this conference provides several unique and engaging educational opportunities for the participant – such as: • Interact with an impressive faculty of Canadian

and international speakers; • Network with colleagues across settings and

disciplines; • Translate scientific discoveries into your practice; • Learn about policy issues that directly affect you; • Raise questions, debate the issues, plan follow-up

studies, and discuss results; • Discuss your own research and observation; • Meet with poster presenters to learn about their

research objectives; and • Visit a number of exhibit booths featuring

products and services specifically designed for professionals in allergy, asthma and immunology.

TARGET AUDIENCE The CSACI Annual Scientific meeting is intended for clinicians, researchers, trainees/students, and allied health professionals involved in research, treatment and management of diseases in allergy, asthma and immunology.

CSACI MISSION AND VISION STATEMENT

The mission of the Canadian Society of Allergy and Clinical Immunology is the advancement of the knowledge and practice of allergy, clinical immunology, and asthma for optimal patient care. The Society is also dedicated to improving the quality of life of people with allergies through research, advocacy, continuing professional development and public education.

EVALUATIONS Delegates can provide feedback on Annual Meeting Sessions they attend by using the Annual Meeting app or by visiting the CSACI website.


ANNUAL GENERAL MEETING All CSACI members are invited to attend the CSACI and CAAIF AGMs Friday, September 30, 2016 1415-1515 Montréal Ballroom Participants will be eligible to win a prize! ACCREDITATION - (Section 1 & Section 3) This event is seeking approval for an accredited group learning activity (Section 1 & Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. Please refer to the final program for accredited sessions. AMA PRA Category 1 Credit™ Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at: www.ama-assn.org/go/internationalcme. CERTIFICATE OF ATTANDANCE All participating delegates will receive an email containing their “Certificate of Attendance” following the meeting. PROGRAM CHANGES AND CANCELLATIONS Please note: The CSACI reserves the right to substitute faculty or to cancel or reschedule sessions because of low enrollment or other unforeseen circumstances.

DISCLOSURE Faculty and Moderator Disclosure: Current CME guidelines state that participants in should be aware of any affiliation or financial interest that could affect the speaker’s presentation(s). Faculty and moderators have completed conflict of interest declarations and those potential conflicts will be listed in the announced at the beginning of each session. The intent of this disclosure requirement is not to prevent a speaker with a conflict of interest from making a presentation but to make known the relationship, in advance, to the audience. It is intended that any conflict be openly identified so that with full disclosure of the facts, attendees may form their own judgments about the presentation. In addition, all members of the annual scientific program committee have also completed their declaration and have announced at each teleconference or meeting any financial interest in commercial organizations that may have a direct or indirect interest in the subject matter of his/her presentation. A “financial interest” may include, but is not limited to, being a direct shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may be holding a position on an advisory committee or some other role of benefit to a sponsoring organization. DISCLAIMER The material presented at this meeting represents the opinion of the speakers and not the views of the CSACI. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the CSACI for reliance on any information presented during these educational activities. The CSACI does not guarantee, warrant or endorse any commercial products or services.

PLEASE NOTE THAT BREAKFASTS AND LUNCHES WILL BE SERVED BOTH ON

THE 9TH AND 11TH FLOORS.

http://www.ama-assn.org/go/internationalcme


VISIT OUR 2016 SPONSORS AND EXHIBITORS The CSACI meeting has proven to be a great opportunity for a collegial interchange of ideas and product information between physicians and our corporate partners. The exhibit area is the exclusive room for meals and breaks. The exhibiting companies and organizations will provide you with the latest information on products and services available to physicians, researchers and allied health professionals in the field of allergy/immunology. For more information on exhibiting companies and organization, please look at the Annual Meeting app.

Don't miss the opportunity to participate in the CSACI Passport Program. Pick up your passport at the CSACI Registration Desk; then visit our participating sponsors and exhibitors, and have your passport signed. Drop off your completed passport at the registration desk.

You will be entered to win some really great prizes, including

one (1) $600 gift card from Best Buy!

PLEASE NOTE THIS MEETING IS FRAGRANCE FREE

APP QR CODE Sponsored by Stallergenes


CSACI SOCIAL EVENTS The CSACI will be holding two social events that will provide you with an opportunity to connect with fellow delegates in a more relaxed environment. This includes the opening reception to be held on Friday, September 30 from 18:30 to 20:00. Dr. Sandy Kapur will present plaques to our corporate partners. On the evening Saturday October 1, the CSACI Executive and Board will be hosting the CSACI dinner. Prizes will be presented for the best posters and awards to pay special homage to our speakers and exemplary CSACI members for their outstanding achievements in the allergy, asthma and immunology field.

CAAIF Inaugural Gala

CAAIF’s Inaugural Gala, to be held on Thursday, September 29, 2016 from 19:00 to 22:00 (Ruelle des Fortifications, inside the World Trade Center) to help raise funds to further research into the causes, prevention and treatment of allergic diseases and to educate health care professionals, patients and

the public about the advances in research and treatment.

Follow the CSACI Annual Meeting on Twitter

While you’re in Montréal, use #CSACI16 when you tweet to

participate in onsite conversations & share what

you’re learning with your colleagues


WEDNESDAY, SEPTEMBER 28, 2016

1530-1645 ROYAL COLLEGE SPECIALTY COMMITTEE MEETING (closed) Riopelle Chair: Dr. Fanny Silviu-Dan 1600-1730 CAAIF BOARD MEETING (closed) Victoria Chair: Dr. Susan Waserman 1800-2130 CSACI DINNER & BOARD MEETING (closed) Victoria Chair: Dr. Sandy Kapur 1830-2000 NREP DINNER & MEETING (closed) St-Jacques Chairs: Dr. Zainab Abdurrahman & Dr. Andy O’Keefe

2100-2230 FIT|NREP|ALLERGEN|CSACI PROGRAM DIRECTORS NETWORKING RECEPTION Grande Place Chair: Dr. Anne Ellis THURSDAY, SEPTEMBER 29, 2016

0715-0800 FIT OSCE BREAKFAST & ORIENTATION Ste-Hélène Chairs: Dr. David Fahmy, Dr. Jaclyn Quirt & Dr. Michael Fein 0715-0800 OSCE EXAMINERS BREAKFAST & ORIENTATION St-Jacques Chairs: Dr. Susan Waserman & Dr. Bill Moote 0810-1000 OSCE CONCURRENT SESSIONS Fortifications Chairs: Dr. Susan Waserman & Dr. Bill Moote 0900-1200 CONCURRENT SESSIONS

TRAINEE CAREER DEVELOPMENT WORKSHOP Palais Chair: Dr. Harissios Vliagoftis

Talking It Up Without Dumbing It Down Speaker: Jocelyne Whitehead, McGill University OBJECTIVES: By the end of these sessions participants will be able to: Discuss your research and other complicated topics for a variety of audiences from job interviews to friends and family.


THURSDAY, SEPTEMBER 29, 2016 1000-1100 PROGRAM DIRECTORS COMMITTEE MEETING St-Jacques Chair: Dr. Lori Connors 1000-1330 FIT WORKSHOP (restricted to Fellows-in-Training) Ste-Hélène Chairs: Dr. David Fahmy, Dr. Jaclyn Quirt & Dr. Michael Fein OBJECTIVES*:

By the end of these sessions participants will be able to:

1000-1030 Introduction to Immunotherapy Victoria Speaker: Dr. Harold Kim, Kitchener, ON Objectives*:

• Discuss Types of immunotherapy available • Review Indications, contraindications and efficacy • Discuss Options for scheduling including pre-seasonal dosing

1030-1130 Case Based Sessions Victoria Speakers: Dr. David Fahmy, Hamilton, ON, Dr. Jaclyn Quirt, Hamilton,

ON & Dr. Harold Kim, Kitchener, ON Objectives*:

• Discuss practical aspects of ordering subcutaneous immunotherapy • Define indications and contraindications of immunotherapy • Discuss practical aspects ordering of sublingual immunotherapy

1130-1230 Lunch & FIT Election

Ste-Hélène 1200-1300 Financial Management, Case Based Sessions Ste-Hélene Speakers: Ms. Jessica Raphael, Mr. Joseph Bakish and Mr. Morris Jacobson

St-Jacques (Richardson GMP Montréal office) and McGill PARTICIPANTS WILL BREAK OUT IN THREE ROOMS FOR GROUP

DISCUSSIONS 1200-1230 SPONSORED LUNCH Montréal

1230-1330 LUNCHEON SYMPOSIUM Montréal


THURSDAY, SEPTEMBER 29, 2016 1345-1400 ABSTRACT ORAL PRESENTATIONS Montréal By the end of this session participants will be able to:

• Describe Canadian allergy and immunology research endeavours

CSACI Eiman Al-Selahi T-cell receptor rearrangement, peripheral blood eosinophilia, and solid tumors

AllerGen Raphael Hanna Cord blood dendritic cell profiles and year one atopic manifestations in the Canadian Healthy Infant Longitudinal Development (CHILD) Study

AllerGen Marylin Desjardins The interleukin-4 (IL-4) & interleukin-21 (IL-21) in vitro assay distinguishes patients with more non-infectious complications of Common Variable Immunodeficiency (CVID)

1400-1810 IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY Montréal Chairs: Françoise Le Deist, CHU Sainte-Justine, University of Montreal and

Christine McCusker Montreal Children’s Hospital, McGill University Health Centre Sponsored by:

1400-1405 Introduction and Welcome

Chaim M. Roifman. The Hospital for Sick Children, University of Toronto, Toronto, ON OBJECTIVES FOR ALL SESSIONS: By the end of these sessions participants will be able to:

1405-1430 Michael Keller, Children’s National Medical Center, Washington, DC Virus-specific T-cell therapy for treatment of SCID and related primary immunodeficiency disorders • Explain the methodology of adoptive T-cell therapy as treatment for

viral infections in patients with PI Disorders • Discuss clinical results of recent and current trials of virus-specific T-cell

therapy • Discuss current advances in virus-specific T-cell therapy, including third

party banking, new viral targets and genetically modified T-cells 1430-1455 Elie Haddad, CHU Ste-Justine, University of Montreal, Montreal, QC

Immune reconstitution after transplantation in SCID • Describe the kinetics of immune reconstitution after Transplantation for

SCID • Explain the impact of immune reconstitution on survival and quality of

life • Delineate the factors that may influence the immune reconstitution


THURSDAY, SEPTEMBER 29, 2016

1400-1810 IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY Cont’d

OBJECTIVES FOR ALL SESSIONS: By the end of these sessions participants will be able to:

Finding new human immunodeficiencies: JAK1 gain-of-function causes a novel autosomal dominant immune dysregulatory and hypereosinophilic syndrome • Idenitfy thatnext generation sequencing is accelerating the discovery

of new human primary PI • Summarize the clinical presentation and treatment options for patients

with JAK1 gain-of-function mutations • Recognize the value of molecularly-targeted "precision Immunology"

1520-1605 Lightning Talks Chairs: Peter Dent, McMaster University and Kyla Hildebrand, UBC

1520-1535 Hani Hadi1 1Department of Allergy, Asthma and Immunology, Children’s Mercy Hospital and Clinics, Kansas City, MO, Could it Have Been Avoided? HSV Encephalitis Secondary to a TLR Defect • Discuss innate immune deficiencies, in particular Toll-Like-Receptor 3

(TLR-3) deficiency in patients with severe herpes simplex virus infections.

1535-1550 Guilhem Cros1, Roxane Labrosse1, Isabel Fernandez1, Françoise Le Deist1, Éric Fortin1, Elie Haddad1 1CHU Sainte-Justine, University of Montreal, Montreal, QC Refractory auto-immune uveitis, successfully treated by sirolimus as an autoimmune manifestation of an hemizygous FoxP3 mutation • Discuss genetic testing of patients with early-onset type 1 diabetes and

other autoimmune manifestations. 1550-1605 Yael Dinur Schejter1, Brenda Reid1, Daniele Merico3, Chaim M. Roifman1,2

1Division of Immunology and Allergy, Department of Pediatrics; 2Canadian Centre for Primary Immunodeficiency; The Hospital for Sick Children, University of Toronto; 3Deep Genomics, University of Toronto, Toronto, Ontario, Novel mutations in the RNU4ATAC gene define obligatory domain changes for Roifman Syndrome • Discuss distinct clinical and genetic aspects of Roifman Syndrome.

1605-1620 BREAK

1620-1635 Adam Byrne1, Reza Alizadehfar1, Christine Lejtenyi1, Bruce Mazer1, Christine McCusker1 1Division of Pediatric Allergy and Immunology, Department of Pediatrics, Montreal Children’s Hospital, McGill University Health Center, Montreal, QC Treatment of Idiopathic Pneumonia Syndrome Post-Hematopoietic Stem Cell Transplant with Etanercept and Rituximab in a STAT3-deficient Hyper-IgE Patient • Explain the treatment of patients with Hyper-IgE Syndrome and the

complications of hematopoietic stem cell transplant in this group.

1455-1515 Stuart Turvey, BC Children’s Hospital, University of British Columbia, Vancouver, BC



1400-1810 IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY – Cont’d

OBJECTIVES FOR ALL SESSIONS: By the end of these sessions participants will be able to:

1635-1650 Hannah Roberts1, Stuart Turvey1 1Division of Allergy and Clinical Immunology,

Department of Pediatrics, University of British Columbia, BC Children’s Hospital, Vancouver, BC, Activated PI3K-delta syndrome is a novel immunodeficiency caused by a gain-of-function mutation in PIK3CD • Utilize a case presentation to strengthen knowledge on Activated PI3K-

delta. 1650-1705 Willa Liao1, Chaim M. Roifman1,2 1Division of Immunology and Allergy,

Department of Pediatrics; 2Canadian Centre for Primary Immunodeficiency; The Hospital for Sick Children, University of Toronto, Toronto, ON A novel mutation in LIG4 leading to severe combined immunodeficiency, eczema, failure to thrive and microcephaly. • Describe the unique clinical presentation and histological findings of an

infant with a novel LIG4 mutation. 1705-1720 Victoria Cook1, Connie L. Yang2, Anna F. Lee3, Kyla J. Hildebrand1, Anne

Junker1, Stuart E. Turvey1 1Division of Clinical Immunology and Allergy, Department of Pediatrics; 2Division of Respirology, Department of Pediatrics; 3Department of Pathology and Laboratory Medicine; University of British Columbia, Vancouver, BC Interstitial Lung disease in infancy: An unusual presentation of CD40 ligand deficiency • Identify interstitial lung disease as a possible presenting feature of

primary immunodeficiency. 1720-1735 Roxane Labrosse1, Guilhem Cros1, Hélène Decaluwe1, Colette Deslandres2,

Françoise Le Deist1, Isabel Fernandez1, Elie Haddad1 1Division of Clinical Immunology & Rheumatology, Department of Pediatrics; 2Division of Gastroenterology, Pediatric Department; CHU Sainte-Justine, University of Montreal, Montreal, QC Neonatal Chronic Granulomatous Disease with Severe Multisystemic Inflammatory Involvement • Discuss very early-onset inflammatory manifestations in chronic

granulomatous disease. 1735-1750 Andrew O’Keefe1, Alison Haynes1, Lesley Turner1, Paul Dancey1 1Division of

Pediatrics, Faculty of Medicine, Memorial University, St. John's, NL. Primary Immunodeficiency's grand masquerade: Leukocyte adhesion deficiency type 1 presenting with pyoderma gangrenosum • Analyze the breadth of presentation of primary immunodeficiency

diseases.

Multiple intestinal atresia with combined immune deficiency: a case report • Recognize multi systemic involvement in a patient presenting with

intestinal atresia and immunodeficiency.

1750-1805 Alexandra Langlois1, Reza Alizadehfar1, Bruce Mazer1, Christine McCusker1 1Division of Pediatric Allergy and Immunology, Department of Pediatrics, Montreal Children’s Hospital, McGill University Health Center, Montreal, QC



1400-1810 IMMUNODEFICIENCY CANADA SYMPOSIUM ON PRIMARY IMMUNODEFICIENCY – Cont’d

1805-1810 Abstract winners (presented by Chaim Roifman and Richard Thompson)

Best abstract – 2nd place best abstract – 3rd place best abstract –

1900-2200 CAAIF INAUGURAL GALA World Trade Center (5 minute walk from Le Westin)

FRIDAY, SEPTEMBER 30, 2016

0700-0730 BREAKFAST 9th and 11th floor (Participants pick up their food and proceed to either Montréal or Fortification

Ballrooms)

0730-0830 BREAKFAST SYMPOSIUM Montréal (Speaker presentation broadcasted simultaneously in Fortification Ballroom) 0840-0900 ABSTRACT ORAL PRESENTATIONS Montréal By the end of this session participants will be able to:

Objectives*: • Describe Canadian allergy and immunology research endeavours

CSACI Hani Hadi Likelihood of sensitization to alternate ingredients in patients evaluated for chocolate allergy

AllerGen Rishma Chooniedass Second chances: reflections on the use of epinephrine for anaphylaxis

CSACI Herman Tam Prescription Patterns of Epinephrine Auto-Injectors for Treatment of Anaphylaxis in Manitoba Children

AllerGen Sofianne Gabrielli Drug-induced anaphylaxis visits: a 4-year follow-up study in two Emergency Departments in Montreal

CSACI Marta Ponce Assessing basophil activation pathways via flow citometry in the context of food allergy

AllerGen Bassel Dawod Examining the role of soluble TLR2 in regulating the development of food allergy



0900-1100 PLENARY SESSION I – FOOD ALLERGY Montréal Chair: Dr. Bruce Mazer

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*: Objectives*:

0900-0925 Food-protein Induced Enterocolitis Speaker: Dr. Kirsi Jarvinen-Seppo, Rochester, NY

Objectives*: • Recognize the clinical presentation of FPIES • Explain the diagnostic workup for FPIES including differential

diagnosis • Describe management and natural history of FPIES

0925-0950 Hypereosinophillic Syndromes Speaker: Dr. Amy Klion, Bethesda, MD Objectives*:

• Define hypereosinophilic syndrome (HES) • Classify HES subtypes using the current approach • Outline therapeutic options for the treatment of HES

0950-1015 Peanut Allergy Cohort - SECTION 3 CREDIT SESSION Speaker: Dr. Elinor Simons, Winnipeg, MB Objectives*:

• Discuss existing knowledge regarding the development and prevention of peanut allergy

• Describe research being undertaken using data from a Canadian birth cohort study and how it may further our understanding of peanut allergy diagnosis and prevention

• Interpret how new information will affect recommendations to families of young children with and without peanut allergy

1015-1040 Markers of Tolerance to Food Allergens Speaker: Dr. Thomas Eiwegger, Toronto, ON Objectives*:

• Summarize the immunological mechanisms (cellular and humoral) which lead to allergic symptoms

• Outline the sequence of events that are modified during allergen immunotherapy

• Discuss mechanistic differences between sublingual and subcutaneous immunotherapy in the literature and whether there is any evidence for differences regarding clinical efficacy

• Describe markers for clinical response and length of effectiveness of allergen immunotherapy

1040-1100 DISCUSSION PERIOD



1100-1120 NUTRITION & NETWORKING BREAK St-Antoine & 9th Floor and 11th floor Ville Marie Montréal

1130-1230 INTEREST SECTION BREAKOUT MEETINGS & ABSTRACT ORAL PRESENTATIONS BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*: Objectives*: Discuss current issues in specialty topics in Allergy and Clinical Immunology

Fortifications Anaphylaxis & Adverse Reactions Chair: Dr. Doug Mack

Topic: Oral Immunotherapy and its readiness for allergist clinical practice. Objectives*: Review recent literature surrounding oral immunotherapy Discuss the application to allergist clinical practice

CSACI Victoria Cook Needs assessment for allergy education mobile app: Review of patient, parent and physician views

CSACI Victoria Cook A Systematic Assessment of mHealth Apps for Atopic Dermatitis Self-Management

Montréal Pediatrics Chair: Dr. Kyla Hildebrand

Topic: A year of advocacy projects in food allergy Objectives*: Describe an advocacy project led by CSACI members involving an international collaboration and systematic review assessing evidence for food avoidance in school settings

Ste-Hélène Immunology Chair: Dr. Stuart Turvey

Topic: Update on Canadian newborn screening for severe combined immunodeficiency (SCID). Objectives: Understand the approach to newborn screening for SCID. Appreciate the current status of newborn screening for SCID across Canada.

Riopelle Rhino-Sinusitis Chair: Dr. Paul Keith Topic:



1130-1230 INTEREST SECTION BREAKOUT MEETINGS & ABSTRACT ORAL PRESENTATIONS BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*: Objectives*: Discuss current issues in specialty topics in Allergy and Clinical Immunology

CONTINUED

McGill Asthma Chair: Dr. Ken Liew Topic: From Basic Science to Clinical Care Objectives*:

• Review relevant basic immunology pertaining to pathophysiology of asthma • Familiarize ourselves with asthma biologics and mechanisms of action

St-Jacques Allied Health Chairs: Ms. Jo-Anne St-Vincent and Ms. Linda Kirste Topic: Caregivers’ Lived Experience of Asthma: Educational Strategies for Knowledge Translation Speaker: Ms. Rishma Chooniedass

1230-1255 LUNCH 9th and 11th floor (Participants pick up their food and proceed to either Montréal or Fortification

Ballrooms)

1255-1355 LUNCH SYMPOSIUM Montréal (Speaker presentation broadcasted simultaneously in Fortification Ballroom)

1355-1410 ABSTRACT ORAL PRESENTATIONS Montréal By the end of this session participants will be able to:


CSACI Persia Pourshahnazari

Study of the effects of complementary and alternative medicine (CAM) on the practice of allergy in primary care and subspecialty settings: preliminary data from the subspecialty survey

AllerGen Young Woong Kim Investigating systemic immune responses in the pathophysiology of allergic rhinitis under the nasal allergen challenge model

AllerGen Mark Tenn Nasal and peripheral blood group 2 innate lymphoid cells (ILC2) levels in response to nasal allergen challenge in participants with allergic rhinitis

CSACI Kateryna Vostretsova Observational study of pollen counts in British Columbia from 2000-2015

1415-1515 CSACI & CAAIF AGMS Montréal Chairs: Dr. Sandy Kapur & Dr. Susan Waserman (CSACI MEMBERS ONLY)



1515-1705 CONCURRENT SESSIONS Montréal HANDS ON|SIMULATION WORKSHOPS - FOR SECTION 3 CREDITS

Chairs: Dr. Lori Connors, Dr. Victoria Cook and Dr. Rebecca Pratt


1515-1525 Introduction and Explanations – Drs. Connors, Cook and Pratt

SESSION 1 - PATCH TESTING ROOM: MCGILL 1525-1555 Group A 1600-1630 Group B 1635-1705 Group C

Objectives*: • Describe indications and contraindications of

patch testing • Apply standard contact allergen patches • Interpret patch test results

SESSION 2 - PROCEDURAL SKILLS ROOM: STE-HÉLÈNE 1525-1555 Group A 1600-1630 Group B 1635-1705 Group C

Objectives*: • Summarize indications and contraindications of

interosseous (IO) and intravenous (IV) access • Describe sterile technique • Insert IO’s and IV’s

SESSION 3 - ADVANCED COMMUNICATION SKILLS ROOM: MONTRÉAL 1525-1555 Group A 1600-1630 Group B 1635-1705 Group C

Objectives*: • Construct and approach to communication with

an emotional patient • Utilize FIFE in clinical encounters • Provide and receive feedback on communication

skills

1515-1700 CONCURRENT SESSIONS Palais MECHANISMS OF ACTION TO THERAPEUTIC APPLICATION IMMUNOTHERAPY FOR ALLERGIC DISEASES – CHALLENGES AND SOLUTIONS Chair: Dr. Harissios Vliagoftis

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*: Objectives*: 1515-1545 Subcutaneous and sublingual allergen immunotherapy: clinical utility

and mechanisms Speaker: Dr. Thomas Eiwegger, Toronto, ON

Objectives*: • Review the immunological mechanisms (cellular and humoral) that

result in allergic symptoms and highlight the sequence of events that are modified during allergen immunotherapy.

• Discuss mechanistic differences between sublingual and subcutaneous immunotherapy in the literature and whether there is any evidence for differences regarding clinical efficacy.

• Review markers for clinical response and on the length of effectiveness of allergen immunotherapy.



1515-1700 CONCURRENT SESSIONS Ramezay MECHANISMS OF ACTION TO THERAPEUTIC APPLICATION IMMUNOTHERAPY FOR ALLERGIC DISEASES – CHALLENGES AND SOLUTIONS CONTINUED


1545-1615 Peptide Immunotherapy: Applications & Mechanisms

Speaker: Dr. Mark Larché, Hamilton, ON Objectives*:

• Review the rationale for the development of novel allergen immunotherapy strategies

• Review clinical results from trials of peptide immunotherapy • Review mechanisms of action of peptide immunotherapy

1615-1645 New Development in Immunotherapy for Food Allergy: Approaches

& Mechanisms Speaker: Dr. Philippe Bégin, Montréal, QC

Objectives*: • Compare current approaches to food immunotherapy • Discuss differences in underlying therapeutic mechanisms

1645-1655 ABSTRACT ORAL PRESENTATIONS By the end of this session participants will be able to: • Describe Canadian allergy and immunology research endeavours

CSACI François Graham Daily peanut introduction in peanut-allergic patients with high reaction thresholds: a case series

AllerGen Elizabeth Simms Ara h 1 peptide immunotherapy protects against severe peanut-induced anaphylaxis and induces PD-1+ CD4+ T cells

1655-1700 Conclusion 1600-1630 NUTRITION BREAK

Foyers of Montréal (11th floor), Ramezay, McGill, and Ste-Hélene (8th Floor)

1715-1845 FIT BOWL* Fortifications Chair: Dr. Anne Ellis 1845-2000 OPENING RECEPTION WITH EXHIBITORS St-Antoine & 9th Floor Ville Marie Montréal


SATURDAY, OCTOBER 1, 2016

0700-0730 BREAKFAST 9th and 11th floor (Participants pick up their food and proceed to either Montréal or Fortification

Ballrooms)

0730-0830 BREAKFAST SYMPOSIUM Montréal (Speaker presentation broadcasted simultaneously in Fortification Ballroom) 0840-0900 ABSTRACT ORAL PRESENTATIONS Montréal By the end of this session participants will be able to:


AllerGen Cristina Longo Weight Status and Time to First Exacerbation in Children with Mild to Moderate Asthma: Is there a Dose-Response Relationship?

AllerGen Keely Loewen Prenatal antibiotic exposure and childhood asthma: a population-based study

AllerGen Danay Maestre-Batlle

The effects of phthalate and toll-like receptor ligand co-exposure on whole blood innate immunology

CSACI Dhaifallah Alotaibi Lipopolysaccharide Inhibits Interleukin–13-induced CCL26 in Human Airway Epithelial cells

AllerGen ChenXi (Yolanda) Yang

Discovery of biomarkers that can diagnose western red cedar asthma

AllerGen Annika Klopp Do infants fed expressed breast milk have an increased risk of developing childhood asthma compared to directly breastfed infants?

0900-1015 PLENARY SESSION II – ASTHMA & RHINITIS Montréal Chair: Dr. Ken Liew

BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*: Objectives*: 0900-0930 Integrating Emerging CRS Concepts into Comprehensive Patient

Care: A Translational Approach Speaker: Dr. Martin Desrosiers, Montréal, QC Objectives:

• Comprehend how emerging concepts in bacteriology, host immunity and barrier function interact in the development and persistence of chronic rhinosinusitis

• Identify the translational implications of basic research as it relates to new therapeutic targets and strategies.

• Elaborate comprehensive management plans for patients with “hard-to-treat” CRS.


SATURDAY, OCTOBER 1, 2016 0900-1015 PLENARY SESSION II – ASTHMA & RHINITIS Montréal Chair: Dr. Ken Liew

CONTINUED BY THE END OF THESE SESSIONS PARTICIPANTS WILL BE ABLE TO*: Objectives*:

0930-0940 Discussion Period

0940-1005 Assessment of Airway Hyperresponsiveness

Speaker: Dr. Donald Cockcroft, Saskatoon, SK Objectives: • Interpret Methacholine challenges • Explain the concepts of direct and indirect stimuli and their

sensitivity and specificity • Identify important caveats re: interpretation of challenges tests



SATURDAY, OCTOBER 1, 2016 0845-1600 CONCURRENT SESSIONS Ramezay ALLIED HEALTH SYMPOSIUM & ABSTRACT ORAL PRESENTATIONS

Chairs: Ms. Jo-Anne St. Vincent & Ms. Linda Kirste


0845-0900 Welcome and introductions

0900-0945 Mechanisms and unusual presentations of anaphylaxis Speaker: Dr. Anne Ellis, Kingston, ON

Objectives*: • Describe the essential pathophysiologic mechanisms of anaphylaxis

and list several causative agents • Diagnose anaphylaxis • Manage anaphylaxis appropriately; recognizing priority role of

epinephrine • Describe the use of ancillary management strategies • Describe features and predictors of biphasic reactions

1000-1100 Celiac disease and other gluten sensitivities Speaker: Dr. Martha Dirks, Montréal, QC Objectives*: • Review the most accurate screening tests to rule in our rule out

suspected celiac disease • Distinguish celiac disease from non-celiac gluten sensitivity and to

be able to counsel patients –clients accordingly • Know the groups at increased risk for developing celiac disease

1115-1225 Oral food challenges risks, benefits and lived experiences Speakers: Dr. Bruce Mazer and Ms. Maria Harvey, Montréal, QC Objectives* – Ms. Harvey: • Describe the role OFC plays in diagnosis-treatment –living with

food allergies • Reflect on the experience of the OFC from patient’s prospective Objectives* – Dr. Mazer • Define life threatening food allergy and contrast to other forms of

food intolerance. • Explain how food allergies are diagnosed and the problems with

the different types of tests used • List the potential benefits of food challenges whether they

demonstrate that a child remains allergic or has outgrown their allergy.


SATURDAY, OCTOBER 1, 2016 0845-1600 CONCURRENT SESSIONS Ramezay ALLIED HEALTH SYMPOSIUM & ABSTRACT ORAL PRESENTATIONS

CONTINUED


1230-1245 Allied Health Poster Presentations By the end of this session participants will be able to: • Describe Canadian allergy and immunology research endeavours

CSACI Saiful Huq Respiratory Analysis of Healthy and ‘Wheezy’ Sounds from Children’s Emergency

CSACI Sara Johnson Qualitative studies of teen experiences living with Food-Induced Anaphylaxis (FIA): a meta-aggregation

1345-1445 Shared decision making: putting patients at the centre of clinical care Speaker: Allyson Shephard

Objectives*: • Explain the fundamental principles of shared decision making and

its relevance to clinical, evidence-based practice • Describe preference misdiagnosis and means to avoid it • Describe decision support strategies and tools that can be

integrated into clinical practice to facilitate shared decision making with patients and families

1445-1530 New and emerging theraputic agents for asthma management Speaker: Dr. Harissios Vliagoftis

Objectives*: • Compare and contrast the opportunities/problems arising from the

variety of corticosteroid, long-acting b agonist and combination inhalers available for the treatment of asthma and the variety of devices used for their delivery

• Describe the role of long acting anticholinergic medications for the treatment of asthma

• Summarize the expanding field of biologics and other targeted therapies for the treatment of asthma and other allergic diseases

1530-1600 Hands-on practice with new inhaler devices Objectives*:

• Teach patients and families how to use various inhaler devices

Grande Place 1600-1700 Allied Health wine & cheese reception (meet & greet) Election of new section co-chair


SATURDAY, OCTOBER 1, 2016 1015-1030 ABSTRACT ORAL PRESENTATIONS Montréal By the end of this session participants will be able to:


AllerGen Michelle North Kingston Allergy Birth Cohort (KABC); Exposome Characteristics and Parentally-Reported Respiratory Outcomes to Age 2

AllerGen John Paul Oliveria IgE+ memory B cells subsets are higher in the airways of mild allergic asthmatics compared to healthy controls

CSACI Yahya Fiteih Role of receptor interacting protein 2 in allergic airway inflammation

CSACI Mihaela Paina Nasal inflammatory biomarkers in pediatric cystic fibrosis with and without nasal polyposis: a cross-sectional comparative study

1030-1200 POSTER VIEWING & JUDGING SESSION Grande Place Chairs: Dr. Anne Ellis & Dr. Harissios Vliagoftis 8th Floor Objectives:

By the end of these sessions, participants will be able to: • Discuss current issues of importance to an interest section • Describe potential collaborations within an interest section • Describe current research in Allergy and Clinical Immunology

1040-1110 NUTRITION BREAK St-Antoine, 9th Floor Ville Marie Montréal 1200-1230 POSTER JUDGING MEETING (closed) St-Paul Chairs: Dr. Anne Ellis & Dr. Harissios Vliagoftis 1215-1245 LUNCH 9th and 11th floor (Participants pick up their food and proceed to either Montréal or Fortification

Ballrooms)

1245-1345 LUNCH SYMPOSIUM Montréal (Speaker presentation broadcasted simultaneously in Fortification Ballroom)


SATURDAY, OCTOBER 1, 2016 1400-1500 PLENARY SESSION III – DRUG ALLERGY & DERMATITIS Montréal Chair: Dr. Harold Kim

Objectives*: By the end of these sessions, participants will be able to:

1400-1420 Evaluation of Drug Allergy: What’s In Our Toolbox? Speaker: Dr. David Khan, Dallas, TX Bram Rose Memorial Lectureship

Objectives*: • Explain the predictive value of drug skin testing • Outline when and how placebo testing can be incorporated in drug

allergy testing. • Discuss the safety, types and interpretation of drug challenges.


1430-1450 Assessment of Contact Dermatitis Speaker: Dr. Linda Moreau, Montréal, QC Objectives*:

• Assess appropriate cases for patch testing • Interpret basic patch testing

1450-1500 Discussion Period 1500-1515 Abstract Oral Presentations

CSACI Savannah Grodecki The Role of Anesthesiologists in the Management of Patients With a Suspected Penicillin Allergy

CSACI Andrew Wakeman Retrospective Review of Beta Lactam Allergy Prevalence in a Referral Population

1515-1645 FREE TIME 1515-1645 CAAIF RUN IN MONT ROYAL

1500-1515 Runners/walkers meet at the Westin Hotel lobby where buses will be waiting to bring

participants to Mont- Royal (see map) 1530-1615 CAAIF RUN/WALK (start and finish) Mont-Royal 1615-1645 End of the Run/Walk – Buses waiting to return participants at the Westin Hotel (see map) Special award medals will be presented at the CSACI dinner on Saturday night.


SATURDAY, OCTOBER 1, 2016 1545-1645 JOURNAL MEETING (closed) Bonsecours Chair: Dr. Richard Warrington 1600-1700 INDUSTRY SUMMIT – ROUNDTABLE DISCUSSION (closed) Viger Corporate Members & CSACI Executive 1745-1900 CASE REPORT PRESENTATIONS Montréal Chairs: Dr. Anne Ellis & Dr. Harissios Vliagoftis

By the end of this session participants will be able to: • Describe Canadian allergy and immunology research endeavours

CSACI Sanju Mishra An adverse reaction to omalizumab in a severe asthmatic patient

CSACI Andrea Burke Questioning the dogma of “physician-diagnosed asthma”

CSACI Chun Che Cross Reactive Conundrums: What is the allergen?

CSACI Lucy Duan Serious allergic reaction with the fifth dose of sublingual immunotherapy for grass-pollen allergy

CSACI Hani Hadi Dramatic resolution of acute necrotizing eosinophilic myocarditis with a brief, high-dose steroid course

CSACI Roxane Labrosse A Pediatric Case of Selective Fixed Drug Eruption to Amoxicillin

CSACI Lana Rosenfield Late presentation of possible terminal compliment deficiency with recurrent Neisseria meningitides infection

CSACI Sanju Mishra Insulin allergy to insulin glargine 300 units/mL (Toujeo®) and other insulin derivatives in a type 2 diabetes mellitus patient

CSACI Ori Scott Long-term Clinical Outcome in Adenosine Deaminase-Deficient Patients following Treatment: A Longitudinal Single-Centre Experience (1985-2015)

1930-2000 CSACI RECEPTION Foyer Fortifications 2000-2200 CSACI DINNER, AWARDS & ABSTRACT PRESENTATIONS Fortifications Chair: Dr. Sandy Kapur


SUNDAY, OCTOBER 2, 2016 0700-0730 BREAKFAST 9th and 11th floor (Participants pick up their food and proceed to either Montréal or Fortification

Ballrooms)

0730-0830 BREAKFAST SYMPOSIUM Montréal (Speaker presentation broadcasted simultaneously in Fortification Ballroom) 0840-1030 PLENARY SESSION IV – LITERATURE REVIEW Montréal Chair: Dr. Sandy Kapur

Objectives*: By the end of these sessions, participants will be able to:

0840-0910 BASIC IMMUNOLOGY Speaker: Dr. Christine McCusker, Montreal, QC Objectives*:

• Outline new cutting edge research in immunology over the past year

• Examine how the data will impact our understanding of immune responses

• Discuss potentials for translation of basic science to the bedside 0910-0940 PEDIATRIC ALLERGY Speaker: Dr. Wade Watson, Halifax, NS Objectives*:

• Describe the results of important pediatric allergy publications in the last 12 months.

• Discuss the implications of new findings in the pediatric allergy literature on your clinical practice.

0940-1000 DISCUSSION PERIOD 1000-1030 NUTRITION & NETWORKING BREAK St-Antoine & 9th Floor Ville Marie Montréal


SUNDAY, OCTOBER 2, 2016 0840-1030 PLENARY SESSION IV – LITERATURE REVIEW - CONTINUED Montréal

1030-1050 Adult Allergy and Immunology Speaker: Dr. Paul Keith, Hamilton, ON Objectives*: • Describe the results of important adult allergy and immunology

publications in the last 12 months. • Discuss the implications of new findings in the adult allergy and

immunology literature on your clinical practice. 1050-1100 Discussion Period

1100-1120 PLENARY SESSION V – HOT TOPIC Montréal APPROACH TO MARIJUANA ALLERGY Chair: Dr. Stuart Carr

Speaker: Dr. Lori Connors, Halifax, NS By the end of this session, participants will be able to: Objectives*: • Explain different types of hypersensitivity reactions to cannabis • Outline major allergen of cannabis and potential cross-reactivity • Generate a diagnostic and therapeutic plan for management of marijuana allergy


1115-1130 CLOSING REMARKS BY NEW CSACI PRESIDENT Montréal Chair: Dr. David Fischer


SAVE THE DATE!

2017 ANNUAL SCIENTIFIC MEETING

October 11-15, 2017 | Toronto, ON


The Canadian Society of Allergy and Clinical Immunology would like to

gratefully acknowledge the following companies: La société canadienne d'allergie et d'immunologie clinique souhaite remercier

chaleureusement les entreprises suivantes:

PATRONS

SILVER

BRONZE

OTHER FINANCIL SUPPORT Meeting app: FIT Bowl:

mailto:http://www.pedia-pharm.com/en/

http://www.medapharma.ca

http://www.merck.ca/english/pages/home.aspx

http://www.shirecanada.com/en/default.aspx

http://www.tevacanadainnovation.com/en

http://www.epipen.ca

http://www.cslbehring.ca/home

http://www.grifols.com

http://www.novartis.ca

http://www.alk-abello.com/CA/Pages/AffWelcome.aspx

CSACI SPONSORED SPEAKERS Dear Meeting Participant, This year, the CSACI brings together an outstanding faculty of international speakers who will share their expertise and insights as they cover the wide spectrum of clinical and basic sciences. To view their bios, please go to the CSACI meeting app.

THURSDAY, SEPTEMBER 29TH

12:30-13:30 Topic: Allergic Rhinitis treatment

guidelines and medical management options

SPONSOR:

Speaker: Dr. Fuad Baroody, Chicago, IL

FRIDAY, SEPTEMBER 30TH

07:30-08:30 Topic: Rupatadine, more than just a

new anti-histamine

SPONSOR:

Dr. Jean-Baptiste Watelet, Belgium

FRIDAY, SEPTEMBER 30TH

12:55-15:55

Topic: HAE

SPONSOR:

Dr. Marco Cicardi, Milan

CSACI 71ST ANNUAL SCIENTIFIC MEETING

SEPTEMBER 29 – OCTOBER 2

http://www.medapharma.ca

mailto:http://www.pedia-pharm.com/en/

SATURDAY, OCTOBER 1ST 07:30-08:30

Topic: Asthma Biologics

SPONSOR:

Dr. Michael Wechsler, Denver, CO

SATURDAY, OCTOBER 1ST 12:45-13:45

Topic: Update on Allergen Immunotherapy with a Focus on the

GAP Trial

SPONSOR:

Dr. Ulrich Wahn, Berlin

SUNDAY, OCTOBER 2nd 07:30-08:30

Topic: Severe Asthma and Biologic Therapy

SPONSOR:

Dr. Peter Howarth, Southampton, UK

CSACI 71ST ANNUAL SCIENTIFIC MEETING RÉUNION...

Documents

Transcript of CSACI 71ST ANNUAL SCIENTIFIC MEETING RÉUNION...